Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -11.64% is 57% above its 5-year average of -27.23%, near the high end of its 5-year range (-45.21%–-11.64%).
52.60% above its 12-month average of -24.55%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.57%.
RETURN ON ASSETS (ROA)
-11.64%
RETURN ON ASSETS (ROA) AVG TTM
-24.55%
RETURN ON ASSETS (ROA) AVG 3Y
-30.16%
RETURN ON ASSETS (ROA) AVG 5Y
-27.23%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+52.60%
CURRENT VS 3Y AVG
+61.41%
CURRENT VS 5Y AVG
+57.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+63.92%
vs the sector median at left
Enliven Therapeutics, Inc.
Market Cap
$3.03B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
Market Cap
$3.06B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$2.99B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
Market Cap
$3.12B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$2.88B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
Market Cap
$3.19B
Return on Assets (ROA)
-7.60%
TTM Avg
-21.23%
3Y Avg
-30.23%
5Y Avg
-24.04%
Market Cap
$2.77B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$3.30B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
Market Cap
$3.31B
Return on Assets (ROA)
-102.47%
TTM Avg
-31.18%
3Y Avg
-31.63%
5Y Avg
-28.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | -11.64% | -24.55% | -30.16% | -27.23% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -44.17% | -37.77% | -27.61% | -21.12% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 5.84% | -21.93% | -47.49% | -47.67% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -57.49% | -99.67% | -60.13% | -103.92% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -52.25% | -41.76% | -70.33% | -55.50% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -7.60% | -21.23% | -30.23% | -24.04% |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 10.36% | 11.11% | 1.40% | -7.68% |
| CareDx, Inc (CDNA)vs › | $3.30B | 20.83% | 2.76% | -12.34% | -9.97% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | -102.47% | -31.18% | -31.63% | -28.00% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 1.56% | -4.54% | -5.50% | -3.43% |
ROA
-11.6%
ROE
-11.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -21.78% |
| 2024-12-31 | -27.33% |
| 2023-12-31 | -26.33% |
| 2022-12-31 | -45.21% |
| 2021-12-31 | -21.83% |
| 2020-12-31 | -20.88% |
| 2019-12-31 | -70.46% |
| 2018-12-31 | -147.14% |
| 2017-12-31 | 0.00% |
